Clinical Trials
Biokin Pharmaceutical Selects Cryoport’s Temperature-Controlled Solutions for its Pending Phase I and Phase II trials
Biokin Pharmaceutical Co. Ltd. a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. , the world's leading temperature-controlled logistics company dedicated to the life sciences industry. Announced Cryoport's full suite of temperature-controlled...
Articles
2019 Trends to Watch For in the Global Clinical Trials Sector
The industry’s pledge to improve the clinical trial experience for participants and investigative sites is taking center stage in 2019. Greenphire’s CEO, Jim Murphy, spoke with World Pharma Today about current trends that will gain momentum this year, and...
Clinical Trials
Clinerion partners with MEDSOFT on expanding clinical research in Georgia
Clinerion will offer its services to hospitals in Georgia, bringing them access to international clinical studies and the use of Patient Network Explorer for academic research. Georgian Medical Software – MEDSOFT, an EHR supplier, will support Clinerion in expanding...
Clinical Trials
Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation...
Clinical Trials
CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor BLU-554
CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase I clinical trial in China for BLU-554 (CS3008). An inhibitor of fibroblast growth factor receptor...
Clinical Trials
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
Bavarian Nordic A/S announced , that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule....
Clinical Trials
Phase 3 Trial of Rova T as Second-line Therapy for Advanced Small-Cell Lung Cancer Halted
AbbVie , a research-based global biopharmaceutical company, announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer (SCLC). An...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read